Pinsent Masons Guides Redx In $880M Cancer Drug Sale
Biotechnology company Redx Pharma PLC on Wednesday said that it has agreed to sell global rights for further development of a cancer-fighting program to Jazz Pharmaceuticals PLC for up to $880...To view the full article, register now.
Already a subscriber? Click here to view full article